After becoming the first company to obtain FDA approval for a 3D printed medication last August, Aprecia Pharmaceuticals Company, Inc. has announced the completion of a $35 million preferred stock financing, giving the 3D printed drug pioneer a big chunk of change with which to commercialize their 3D printed tablets and to develop even more.
Aprecia made headlines last year when the company first announced and then obtained FDA approval for a 3D printed drug called SPRITAM® (levetiracetam). Having licensed ZCorp’s binder jetting technology, responsible for many of the full-color prints that populate the 3D printing world, the company was able to produce this anti-epilepsy tablet as an instantly-dissolved, high dose medication.…
The original post $35 Million to Fund Drug 3D Printing from Aprecia appeared first on 3D Printing Industry.